



FOR IMMEDIATE RELEASE

Thursday, April 30, 2026

ASOP Global Statement in Support of the House Agriculture Subcommittee FY2027 FDA Appropriations Report Language

Provisions addressing counterfeit medicines, illegal drug imports, international mail facilities, and pharmacy compounding reflect critical patient safety priorities

WASHINGTON, DC (April 30, 2026) – The [Alliance for Safe Online Pharmacies](#) (ASOP Global) commends the House Appropriations Committee for including strong patient safety provisions in the [FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations - Report](#). The report language directly reinforces FDA's core mandate to protect U.S. consumers from harmful, unapproved pharmaceutical ingredients and illicit, unsafe drugs — and ASOP Global is pleased to express its strong support.

Counterfeit Medicines

Counterfeit, misbranded, and adulterated drugs — particularly GLP-1 and GIP/GLP-1 products sourced from China and other foreign countries — pose a direct and serious threat to patient health and safety. FDA's authority to prevent such products from entering the U.S. market is one of its most fundamental consumer protection responsibilities. ASOP Global strongly supports the Committee's direction that FDA, in coordination with the U.S. Department of Justice (DOJ) and other federal law enforcement agencies, deploy the full range of available regulatory and enforcement tools — including warning letters, seizures, injunctions, criminal referrals, and import refusals — to keep these dangerous products away from U.S. consumers. Robust, coordinated federal enforcement is not optional; it is essential.

Illegal Imports of Unapproved New Drugs

FDA's approval process exists for a reason: to ensure that the drugs Americans take are safe, effective, and manufactured under proper conditions. When third-party brokers — including those operating through employer-sponsored health plans — circumvent that process by facilitating access to unapproved and misbranded drugs from uninspected foreign supply chains, they undermine the very system designed to protect patients. These schemes, often marketed as "alternative funding programs" (AFPs), expose patients managing serious conditions such as HIV, cancer, and hepatitis to unknown ingredients, incorrect dosages, contamination, and dangerous medication errors. ASOP Global strongly supports the Committee's call for a comprehensive FDA report on this issue and urges the agency to use all available enforcement authorities to protect patients from these unregulated and potentially life-threatening products.

International Mail Facilities

International mail facilities represent a critical — and often underutilized — line of defense against the flow of illegal, counterfeit, and unapproved drugs into the United States. Strengthening FDA's interdiction and data collection capabilities at these entry points is a direct extension of the agency's mission to safeguard the U.S. drug supply. ASOP Global supports the Committee's request for a detailed report classifying refused import products by controlled and

non-controlled status, and further by counterfeit, misbranded, or unapproved designation. Greater transparency and data at the border will help FDA and its law enforcement partners better understand the scope of the problem and direct resources where they are needed most to protect American consumers.

Pharmacy Compounding Advisory Committee (PCAC)

The proliferation of unsafe compounding practices across the United States — particularly the compounding of injectable drugs — poses serious and growing risks to patient health and safety. Improperly compounded injectables can expose patients to contamination, incorrect dosing, and other potentially life-threatening harms. It is precisely because of these risks that the composition of the PCAC matters so much: FDA depends on the Committee's expertise to make sound, science-based decisions about compounding policy that protect patients. ASOP Global joins the Committee in recommending that PCAC voting members possess relevant compounding expertise that ensures FDA can fulfill its mandate to protect consumers from unsafe compounded products.

ASOP Global thanks the Committee for its leadership and its commitment to strengthening FDA's ability to protect Americans from unsafe and illegal medicines. We look forward to continuing to work with Congress and FDA in support of this vital public health mission.

###

About ASOP Global

The Alliance for Safe Online Pharmacies (ASOP Global), a 501(c)(4) non-profit organization headquartered in Washington, D.C., with activities in the U.S., Canada, Europe, Latin America, and Asia, is dedicated to protecting consumers around the world, ensuring safe access to medications, and combating illegal online drug sellers. Learn more at buysaferx.pharmacy.